INT'L GROUP(SZ:000411)2025-04-27 07:35Revenue and Profitability - Revenue for Q1 2025 was CNY 8,436,943,741.35, a decrease of 1.87% compared to CNY 8,597,940,087.94 in the same period last year[5] - Net profit attributable to shareholders was CNY 100,801,310.48, down 5.70% from CNY 106,894,805.02 year-over-year[5] - Basic earnings per share decreased by 6.10% to CNY 0.1941 from CNY 0.2067 in the previous year[5] - Total operating revenue for the current period was ¥8,436,943,741.35, a decrease of 1.87% from ¥8,597,940,087.94 in the previous period[18] - Net profit for the current period was ¥119,122,931.68, down 7.06% from ¥128,524,787.80 in the previous period[18] - Basic earnings per share decreased to CNY 0.1941 from CNY 0.2067, indicating a decline in profitability on a per-share basis[19] - Diluted earnings per share also fell to CNY 0.1854 from CNY 0.1974, further highlighting the decrease in earnings[19] Assets and Liabilities - Total assets increased by 11.67% to CNY 16,340,244,312.38 from CNY 14,632,477,002.42 at the end of the previous year[5] - Current liabilities rose significantly to ¥10,318,108,652.14 from ¥8,739,555,232.39, an increase of 18.06%[16] - The company's total assets increased to ¥16,340,244,312.38 from ¥14,632,477,002.42, representing a growth of 11.66%[16] - The total equity attributable to the parent company increased to ¥4,739,552,708.65 from ¥4,637,220,801.37, a rise of 2.20%[16] Cash Flow - Cash flow from operating activities showed a negative net amount of CNY -2,664,749,856.70, worsening from CNY -1,914,183,258.10 in the previous year[5] - The net cash flow from operating activities decreased significantly to -2,664,749,856.70, primarily due to a reduction in cash received from sales and an increase in cash paid for purchases and services[10] - The cash and cash equivalents decreased by 3,282.40% to -424,517,843.97, primarily due to reduced net cash flow from operating activities[10] - The total cash and cash equivalents at the end of the period were CNY 850,578,247.41, down from CNY 1,349,592,698.39 in the previous period[21] - The net increase in cash and cash equivalents was CNY -424,517,843.97, contrasting with a net increase of CNY 13,339,537.64 in the previous period, indicating cash flow challenges[21] Investments and Expenditures - Research and development expenses rose significantly by 126.10% to CNY 4,552,638.58, primarily due to increased investment in the cold chain logistics project[9] - Cash outflow for the acquisition of fixed assets and other long-term assets rose by 77.37% to 32,937,456.96, attributed to increased investments in renovation projects[10] - The company invested CNY 32,937,456.96 in fixed assets, intangible assets, and other long-term assets, a substantial increase from CNY 18,569,626.50 in the previous period[21] Financing Activities - Short-term borrowings surged by 106.02% to CNY 3,651,826,139.26, mainly due to increased bank loans[9] - The company received cash of 153,000,000.00 related to financing activities, primarily from commercial acceptance bill discounts[10] - Cash inflow from financing activities increased to CNY 3,760,132,308.44, up from CNY 3,202,490,084.20 in the previous period, reflecting a stronger financing position[21] Shareholder Information - The total number of common shareholders at the end of the reporting period was 23,329[12] - Zhejiang International Trade Group Co., Ltd. held 28.90% of shares, making it the largest shareholder with 150,846,487 shares[12] - Zhejiang Pharmaceutical Health Industry Group Co., Ltd. owned 23.43% of shares, totaling 122,277,151 shares[12] Tax and Subsidies - The company received government subsidies amounting to CNY 5,156,166.48, contributing positively to the financial results[6] - The net cash received from tax refunds increased significantly by 1,112.86% to CNY 346,148.04 compared to CNY 28,539.75 in the previous year[9] - The company received CNY 346,148.04 in tax refunds, significantly higher than CNY 28,539.75 in the previous period, indicating improved tax recovery[20]